| Literature DB >> 22272148 |
Mihai V Putz1, Marius Lazea, Ana-Maria Putz, Corina Duda-Seiman.
Abstract
The classical method of quantitative structure-activity relationships (QSAR) is enriched using non-linear models, as Thom's polynomials allow either uni- or bi-variate structural parameters. In this context, catastrophe QSAR algorithms are applied to the anti-HIV-1 activity of pyridinone derivatives. This requires calculation of the so-called relative statistical power and of its minimum principle in various QSAR models. A new index, known as a statistical relative power, is constructed as an Euclidian measure for the combined ratio of the Pearson correlation to algebraic correlation, with normalized t-Student and the Fisher tests. First and second order inter-model paths are considered for mono-variate catastrophes, whereas for bi-variate catastrophes the direct minimum path is provided, allowing the QSAR models to be tested for predictive purposes. At this stage, the max-to-min hierarchies of the tested models allow the interaction mechanism to be identified using structural parameter succession and the typical catastrophes involved. Minimized differences between these catastrophe models in the common structurally influential domains that span both the trial and tested compounds identify the "optimal molecular structural domains" and the molecules with the best output with respect to the modeled activity, which in this case is human immunodeficiency virus type 1 HIV-1 inhibition. The best molecules are characterized by hydrophobic interactions with the HIV-1 p66 subunit protein, and they concur with those identified in other 3D-QSAR analyses. Moreover, the importance of aromatic ring stacking interactions for increasing the binding affinity of the inhibitor-reverse transcriptase ligand-substrate complex is highlighted.Entities:
Keywords: HIV-1 inhibitory activity; QSAR structural domains; Thom’s catastrophe polynomials; minimum statistical paths; statistical factors
Mesh:
Substances:
Year: 2011 PMID: 22272148 PMCID: PMC3257145 DOI: 10.3390/ijms12129533
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The QSAR working table for Equation (1) in the presence of M-structural descriptors for N-compounds with known activities.
| Observed Activity | Structural | Predictor | Variables | ||
|---|---|---|---|---|---|
| … | … | ||||
| … | … | ||||
| … | … | ||||
| ⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ |
| … | … | ||||
Thom’s Classification of Elementary Catastrophes [36,37].
| Name | Co-dimension | Co-rank | Universal unfolding | Parametric Representation |
|---|---|---|---|---|
| Fold | 1 | 1 | ||
| Cusp | 2 | 1 | ||
| Swallow tail | 3 | 1 | ||
| Butterfly | 4 | 1 | ||
| Hyperbolic umbilic | 3 | 2 | ||
| Elliptic umbilic | 3 | 2 | ||
| Parabolic umbilic | 4 | 2 |
Algebraic realization of Thom’s elementary catastrophes as uni- and bi- nonlinear QSARs. The systematics of the sub-indices indicate consecutive coupled pairs, where each pair is interpreted as: the index of a structural factor followed by its power.
| Model | QSAR Equation |
|---|---|
| QSAR-(I) | |
| Fold | |
| Cusp | |
| Swallow tail | |
| Butterfly | |
| QSAR- (II) | |
| Hyperbolic umbilic | |
| Elliptic umbilic | |
| Parabolic umbilic | |
Actual working reverse transcriptase pyridinone inhibitors grouped in Gaussian (G) and non-Gaussian (NG) molecular congeneric sets with their structural information (hydrophobicity, Log P; molecular polarizability POL [Å3] and total optimized energy of formation H [kcal/mol]) computed upon the semi-empirical PM3 method [42], along with their observed activity A = Log (1/IC50) [24].
| No. | Type | WORKING MOLECULES | Aobs | QSAR parameters | |||
|---|---|---|---|---|---|---|---|
| Structure | Name | Log (1/IC50) | Log P | POL (Å3) | H (kcal/mol) | ||
| 1. | G1 | 3-{[(6′-azabenzofuran-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 3.98 | −0.54 | 31.21 | −14.67 | |
| 2. | G2 | 3-{[(5′-azabenzofuran-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 4.49 | −0.54 | 31.21 | −16.195 | |
| 3. | G3 | 3-{[(pyridine-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 4.82 | 0.21 | 27.87 | -5.854 | |
| 4. | G4 | 3-benzylamino-5-ethyl-6-methylpyridin-2(1H)-one | 5.27 | 0.67 | 28.58 | −11.659 | |
| 5. | G5 | 3-{[(1′,3′-naftoxazol-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.57 | 1.20 | 38.48 | −1.878 | |
| 6. | G6 | 3-{[(1′-benzopyran-4′-one-3′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.96 | −0.71 | 33.84 | −61.455 | |
| 7. | G7 | 3-{[(benzopyridine-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.28 | 1.16 | 35.14 | 11.246 | |
| 8. | G8 | 3-{[(1′,3′-benzothiazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.46 | 0.54 | 33.57 | 17.808 | |
| 9. | G9 | 3-{[(4′-methylbenzoxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.92 | 0.67 | 33.05 | −27.613 | |
| 10. | G10 | 3-{[(4′,7′-dichlorobenzofuran-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 7.24 | 0.88 | 35.78 | −33.749 | |
| 11. | G11 | 3-{[(4′,7′-dimethylbenzoxazol-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 7.7 | 1.13 | 34.88 | −38.048 | |
| 12. | G12 | 3-{[(4′,7′-dichlorobenzoxazol-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 7.72 | 1.24 | 35.07 | −30.071 | |
| 13. | G13 | 3-[(4′,7′-dimethylbenzoxazol-2′-yl) ethyl]-5-ethyl-6-methylpyridin-2(1H)-one | 7.55 | 2.62 | 35.37 | −47.701 | |
| 14. | G14 | 3-[(4′,5′,6′,7′-tetrahydrobenzoxazole-2′-yl) ethyl]-5-ethyl-6-methylpyridin-2(1H)-one | 7.24 | −0.02 | 32.08 | −63.299 | |
| 15. | G15 | 3-{[(4′-methoxybenzoxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.74 | −0.05 | 33.68 | −54.452 | |
| 16. | G16 | 3-[(4′,5′,6′,7′-tetrahydrobenzoxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.55 | −1.50 | 31.59 | −50.643 | |
| 17. | G17 | 3-{[(benzothiophene-2′-yl) methyl] amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.30 | 0.19 | 34.28 | 11.703 | |
| 18. | G18 | 3-{[(5′-methylbenzoxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.90 | 0.67 | 33.05 | −27.741 | |
| 19. | G19 | 3-[(benzopyridine-2′-yl) ethyl]5-ethyl-6-methylpyridin-2(1H)-one | 5.61 | 2.71 | 35.62 | 3.331 | |
| 20. | G20 | 3-{[(indol-2′-yl) methyl] amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.36 | −0.34 | 32.63 | 4.727 | |
| 21. | G21 | 3-{[(quinazolin-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.12 | 0.02 | 31.92 | 8.171 | |
| 22. | G22 | 3-{[(indol-3′-yl)methyl] amino}-5-ethyl-6-methylpyridin-2(1H)-one | 4.65 | −0.43 | 32.63 | 2.957 | |
| 23. | G23 | 3-(β-phenilethyl)-5-ethyl-6-methylpyridin-2(1H)-one | 4.30 | 2.36 | 29.06 | −23.245 | |
| 24. | NG1 | 3-{[(4′-quinozolone-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.60 | −0.47 | 33.85 | −36.959 | |
| 25. | NG2 | 3-{[(3′,4′-diazobenzofuran-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.72 | 0.05 | 30.50 | −8.120 | |
| 26. | NG3 | 3-{[(7′-hydroxybenzoxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.36 | −0.08 | 31.85 | −62.189 | |
| 27. | NG4 | 3-[(4′,7′-dichlorobenzoxazole-2′-yl) ethyl]-5-ethyl-6-methylpyridin-2(1H)-one | 7.85 | 2.72 | 35.55 | −39.459 | |
| 28. | NG5 | 3-{[(7′-ethylbenzoxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.59 | 1.06 | 34.88 | −34.478 | |
| 29. | NG6 | 3-[(5′-phenyl-oxazole-2′-yl) ethyl]-5-ethyl-6-methylpyridin-2(1H)-one | 6.41 | 0.96 | 35.17 | −21.361 | |
| 30. | NG7 | 3-[(benzothiazole-2′-yl) ethyl]-5-ethyl-6-methylpyridin-2(1H)-one | 6.43 | 2.02 | 34.06 | 8.873 | |
| 31. | NG8 | 3-{[(2′naphtyl) methyl] amino}-5-ethyl-6-methylpyridin-2(1H)-one | 6.34 | 1.67 | 35.85 | 5.495 | |
| 32. | NG9 | 3-{[(5′-phenyl-oxazole-2′-yl) methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one | 5.63 | −0.53 | 34.69 | −10.850 | |
Figure 1Gaussian (G) and non-Gaussian (NG) screening of the observed activities of the working molecules in Table 4 grouped into trial and test congener series.
Correlation equations for the Group-I models of Table 3 and the molecular structures and data of Table 4.
| Catastrophe | QSAR Model | Π | |||||||
|---|---|---|---|---|---|---|---|---|---|
| QSAR (I) | 0.228 | 0.984 | 4.317 | 22.344 | 7.854 | 1.150 | 0.143 | 8.963 | |
| 0.554 | 0.989 | 1.784 | −0.832 | −0.292 | 9.284 | 1.158 | 2.147 | ||
| 0.476 | 0.987 | 2.074 | 20.597 | 7.24 | 6.156 | 0.768 | 7.57 | ||
| Fold (F) | 0.382 | 0.986 | 2.581 | 22.936 | 8.062 | 1.705 | 0.213 | 8.468 | |
| 0.601 | 0.989 | 1.646 | −1.422 | −0.45 | 5.650 | 0.704 | 1.859 | ||
| 0.481 | 0.987 | 2.053 | 20.095 | 7.063 | 3.01 | 0.375 | 7.365 | ||
| Cusp (C) | 0.348 | 0.985 | 2.832 | 16.120 | 5.666 | 0.872 | 0.109 | 6.335 | |
| 0.713 | 0.992 | 1.391 | 2.240 | 0.787 | 6.558 | 0.818 | 1.796 | ||
| 0.764 | 0.993 | 1.300 | 19.802 | 6.960 | 8.864 | 1.105 | 7.166 | ||
| Swallow tail (ST) | 0.575 | 0.989 | 1.720 | 18.665 | 6.561 | 2.222 | 0.277 | 6.788 | |
| 0.715 | 0.992 | 1.387 | 0.45 | 0.158 | 4.708 | 0.587 | 1.515 | ||
| 0.763 | 0.993 | 1.302 | 15.608 | 5.486 | 6.263 | 0.781 | 5.692 | ||
| Butterfly (B) | 0.578 | 0.989 | 1.711 | 15.169 | 5.332 | 1.704 | 0.212 | 5.604 | |
| 0.718 | 0.992 | 1.382 | −0.355 | −0.125 | 3.619 | 0.451 | 1.459 | ||
| 0.856 | 0.996 | 1.163 | 19.088 | 6.709 | 9.349 | 1.166 | 6.908 |
the statistical Pearson correlation factor;
computed from Equation (7);
computed from Equation (9);
computed from Equation (10) with ;
computed from Equation (11) with ;
computed from Equation (8).
Single-structure matrices of the Euclidean distances ΔΠ of the QSAR and catastrophe models’ relative statistics of Table 6 employing Equation (12); note that for the degenerate models of Table 6 that one is employed that displays higher relative statistical power ( Π).
| Log P^POL | |||
|---|---|---|---|
| 0.675 | 0.810 | 1.005 | |
| 0.139 | 1.414 | ||
| 1.531 |
Correlation equations for the Group-II models of Table 3 and the molecular structures and data of Table 4.
| Catastrophe | QSAR Model | RPearson | RALG | Π | |||||
|---|---|---|---|---|---|---|---|---|---|
| QSAR (II) | 0.556 | 0.989 | 1.778 | −0.702 | −0.245 | 4.464 | 0.763 | 1.9504 | |
| 0.556 | 0.989 | 1.778 | 18.564 | 6.489 | 4.468 | 0.764 | 6.771 | ||
| 0.728 | 0.992 | 1.363 | −1.151 | −0.402 | 11.302 | 1.932 | 2.398 | ||
| Hyperbolic umbilic (HU) | 0.715 | 0.992 | 1.387 | −2.215 | −0.774 | 3.561 | 0.609 | 1.701 | |
| 0.736 | 0.992 | 1.3485 | 19.328 | 6.756 | 4.019 | 0.687 | 6.923 | ||
| 0.755 | 0.993 | 1.315 | −0.79 | −0.276 | 4.503 | 0.770 | 1.549 | ||
| Elliptic umbilic (EU) | 0.757 | 0.993 | 1.312 | −2.548 | −0.891 | 3.582 | 0.612 | 1.670 | |
| 0.722 | 0.992 | 1.374 | 1.866 | 0.652 | 2.908 | 0.497 | 1.600 | ||
| 0.843 | 0.995 | 1.181 | 20.638 | 7.214 | 6.542 | 1.118 | 7.395 | ||
| Elliptic umbilic (EU) | 0.851 | 0.995 | 1.170 | 17.047 | 5.958 | 7.015 | 1.199 | 6.189 | |
| 0.857 | 0.996 | 1.162 | 3.124 | 1.092 | 7.346 | 1.256 | 2.029 | ||
| 0.853 | 0.996 | 1.167 | 0.532 | 0.186 | 7.120 | 1.217 | 1.696 | ||
| Parabolic umbilic (PU) | 0.722 | 0.992 | 1.374 | 1.817 | 0.635 | 2.905 | 0.497 | 1.593 | |
| 0.703 | 0.992 | 1.411 | −2.219 | −0.776 | 2.611 | 0.446 | 1.671 | ||
| Parabolic umbilic (PU) | 0.874 | 0.996 | 1.140 | 20.243 | 7.075 | 8.645 | 1.478 | 7.317 | |
| 0.767 | 0.993 | 1.295 | 16.828 | 5.882 | 3.815 | 0.652 | 6.058 | ||
| 0.841 | 0.995 | 1.183 | 0.386 | 0.135 | 6.447 | 1.102 | 1.623 | ||
| 0.856 | 0.996 | 1.163 | 3.074 | 1.074 | 7.292 | 1.246 | 2.015 |
the statistical Pearson correlation factor;
computed from Equation (7);
computed from Equation (9);
computed from Equation (10) with ;
computed from Equation (11) with ;
computed from Equation (8).
Single-structure matrices of the Euclidean distances ΔΠ of the QSAR and catastrophe models’ relative statistics of Table 5 employing Equation (12).
| Log P | ||||
|---|---|---|---|---|
| 1.750 | 2.645 | 2.905 | 3.627 | |
| 2.411 | 1.732 | 2.865 | ||
| 1.437 | 1.174 | |||
| 1.231 |
Differences Δ2Π between the single-structure matrices of the Euclidean distances in Table 7.
| |Log P ÷ POL| | ||||
|---|---|---|---|---|
| 1.233 | 1.446 | 2.076 | 2.797 | |
| 1.094 | 1.015 | 2.341 | ||
| 0.767 | 0.191 | |||
| 0.917 |
Predicted activity as computed for the non-Gaussian molecules of Table 4 with the models of Table 5 founded along the minimum paths of Table 7; for each predicted model, its correlation with the observed activity is indicated at the bottom of the table.
| Model | ||||||
|---|---|---|---|---|---|---|
| Molecule | ||||||
| 5.586 | 6.179 | 5.294 | 5.094 | −20.595 | 5.687 | |
| 5.729 | 4.885 | 4.294 | 5.719 | −9.764 | 4.360 | |
| 5.676 | 0.415 | 4.708 | 5.531 | −13.457 | −7.932 | |
| 5.729 | 6.156 | 5.149 | 6.657 | −29.709 | 5.259 | |
| 6.487 | 6.141 | 5.309 | 6.705 | −25.700 | 5.923 | |
| 6.399 | 5.438 | 5.258 | 6.708 | −27.365 | 5.219 | |
| 6.903 | 5.631 | 5.319 | 5.311 | −21.540 | 5.984 | |
| 6.904 | 5.334 | 5.027 | 5.995 | −31.693 | 5.566 | |
| 5.580 | 4.9357 | 5.328 | 5.054 | −24.666 | 4.383 | |
Predicted activity as computed for the non-Gaussian molecules of Table 4 with the models of Table 6 founded along the minimum paths of Table 9; for each predicted model, its correlation with the observed activity is indicated at the bottom of the table.
| Model | ||||||
|---|---|---|---|---|---|---|
| Molecule | ||||||
| 6.0865 | 5.918 | 5.308 | 5.387 | 5.351 | 7.210 | |
| 5.581 | 5.839 | 5.399 | 5.448 | 4.816 | 4.578 | |
| 6.785 | 6.132 | 7.526 | 5.686 | 1.423 | 7.234 | |
| 7.115 | 6.642 | 6.037 | 6.289 | 5.480 | 7.765 | |
| 6.495 | 7.382 | 6.853 | 7.277 | 6.033 | 7.629 | |
| 6.163 | 7.291 | 6.426 | 7.104 | 7.338 | 7.647 | |
| 5.790 | 7.388 | 6.087 | 7.615 | 6.879 | 6.547 | |
| 5.761 | 7.560 | 6.330 | 7.640 | 7.895 | 7.447 | |
| 5.467 | 5.755 | 4.786 | 5.177 | 7.586 | 7.303 | |
Figure 23D-representations of the QSAR and catastrophe activities for the tested models of Table 11 in the range of the structural indicators (Log P, Pol, H) as abstracted from Table 4.
Figure 3Determination of the structural domains of pyridinone-derivative type non-nucleoside reverse transcriptase inhibitors in the same range of structural descriptors by employing the principles of hydrophobicity, minimum polarizability, binding energy, and the minimum difference between the polynomial activity models of Figure 2; the hydrophobic pocket was identified in the p66 subunit of HIV-1-rt of specific transferase R221239 [48,49].